CL2021003275A1 - Compuestos para tratar enfermedad respiratoria. - Google Patents

Compuestos para tratar enfermedad respiratoria.

Info

Publication number
CL2021003275A1
CL2021003275A1 CL2021003275A CL2021003275A CL2021003275A1 CL 2021003275 A1 CL2021003275 A1 CL 2021003275A1 CL 2021003275 A CL2021003275 A CL 2021003275A CL 2021003275 A CL2021003275 A CL 2021003275A CL 2021003275 A1 CL2021003275 A1 CL 2021003275A1
Authority
CL
Chile
Prior art keywords
compounds
respiratory disease
treat respiratory
diseases
tmem16a
Prior art date
Application number
CL2021003275A
Other languages
English (en)
Inventor
Stephen Collingwood
Clive Mccarthy
Jonathan David Hargrave
Duncan Alexander Hay
Thomas Beauregard Schofield
Peter Ingram
Matthew Smith
Christopher Stimson
Edward Walker
Albert Ma
Naomi Went
Someina Khor
Original Assignee
Tmem16A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1908451.6A external-priority patent/GB201908451D0/en
Priority claimed from GBGB1917691.6A external-priority patent/GB201917691D0/en
Application filed by Tmem16A Ltd filed Critical Tmem16A Ltd
Publication of CL2021003275A1 publication Critical patent/CL2021003275A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de fórmula general (I) y sus formas tautoméricas, todos los enantiómeros y variantes isotópicas, y sales y solvatos de estos: (I) (AA) en donde representa un enlace simple o un enlace doble y R1, R2, X1, X2, X3, X4, X5, Y y Z son como se define en la presente; son útiles para el tratamiento de enfermedades respiratorias y otras enfermedades y afecciones moduladas por TMEM16A.
CL2021003275A 2019-06-12 2021-12-09 Compuestos para tratar enfermedad respiratoria. CL2021003275A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1908451.6A GB201908451D0 (en) 2019-06-12 2019-06-12 Compounds for treating respiratory disease
GBGB1917691.6A GB201917691D0 (en) 2019-12-04 2019-12-04 Compounds for treating respiratory disease

Publications (1)

Publication Number Publication Date
CL2021003275A1 true CL2021003275A1 (es) 2022-08-19

Family

ID=71120193

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003275A CL2021003275A1 (es) 2019-06-12 2021-12-09 Compuestos para tratar enfermedad respiratoria.

Country Status (16)

Country Link
US (1) US20220098167A1 (es)
EP (1) EP3983389A1 (es)
JP (1) JP2022535980A (es)
KR (1) KR20220050126A (es)
CN (1) CN114269721A (es)
AU (1) AU2020290049A1 (es)
BR (1) BR112021025079A2 (es)
CA (1) CA3141394A1 (es)
CL (1) CL2021003275A1 (es)
CO (1) CO2022000084A2 (es)
CR (1) CR20220006A (es)
IL (1) IL288793A (es)
MA (1) MA56186A (es)
MX (1) MX2021015214A (es)
PE (1) PE20221003A1 (es)
WO (1) WO2020249957A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4225742A4 (en) 2020-10-05 2024-11-06 Enliven Inc 5- 6-AZAINDOL COMPOUNDS FOR INHIBITING BCR-ABL TYROSINE KINASES
CN116745267A (zh) * 2020-12-11 2023-09-12 跨膜蛋白16A有限公司 用于治疗呼吸系统疾病的苯并咪唑衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521907A1 (en) * 2003-04-10 2004-10-21 Pfizer Inc. Bicyclic compounds as nr2b receptor antagonists
US20050239767A1 (en) * 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
WO2007079164A2 (en) * 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
DE102006032824A1 (de) * 2006-07-14 2008-01-17 Bayer Healthcare Ag Substituierte Indazole
EP3251694A1 (en) * 2007-08-03 2017-12-06 Summit (Oxford) Limited Drug combinations for the treatment of duchenne muscular dystrophy
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011099832A2 (en) * 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2013033269A1 (en) * 2011-08-29 2013-03-07 Coferon, Inc. Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
EP3612180B1 (en) * 2017-04-17 2023-10-11 The Regents of the University of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
CA3111392A1 (en) * 2018-09-04 2020-03-12 Magenta Therapeutics, Inc. Aryl hydrocarbon receptor antagonists and methods of use

Also Published As

Publication number Publication date
MA56186A (fr) 2022-04-20
CA3141394A1 (en) 2020-12-17
CO2022000084A2 (es) 2022-04-08
AU2020290049A1 (en) 2022-02-03
JP2022535980A (ja) 2022-08-10
CN114269721A (zh) 2022-04-01
WO2020249957A1 (en) 2020-12-17
CR20220006A (es) 2022-06-06
PE20221003A1 (es) 2022-06-15
BR112021025079A2 (pt) 2022-02-15
IL288793A (en) 2022-02-01
KR20220050126A (ko) 2022-04-22
EP3983389A1 (en) 2022-04-20
US20220098167A1 (en) 2022-03-31
MX2021015214A (es) 2022-04-06

Similar Documents

Publication Publication Date Title
CO2022000084A2 (es) Compuestos para tratar enfermedad respiratoria
DOP2022000172A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
DOP2020000249A (es) N-benzisoxazolilo bencenosulfonamidas como inhibidores de kat
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
NI201700029A (es) Compuestos y composiciones como inhibidores de quinasa raf.
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CO2017009994A2 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
CL2019003515A1 (es) Compuestos heteroaromáticos como inhibidores de vanina.
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
CO2023014721A2 (es) Compuestos heterocíclicos
DOP2013000051A (es) Compuestos heterociclico y sus usos
CY1124479T1 (el) Ενωσεις που περιεχουν υποκατεστημενο αζωτο
CL2020001047A1 (es) Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma.
CO2020010042A2 (es) Compuestos de alquinileno sustituidos como agentes anticancerígenos
CL2017002148A1 (es) Derivados de tetrahidropiranil benzamida
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
AR102634A1 (es) Compuestos aromáticos sustituidos y composiciones farmacéuticas para la autorreparación y regeneración del tejido
CL2022001302A1 (es) Compuestos novedosos para el diagnóstico, tratamiento y prevención de enfermedades asociadas con la agregación de
CO2020014069A2 (es) Sales de meglumina de tienopirimidinas
ECSP22046595A (es) Procesos e intermediario para la preparaci?n de oxetan-2-ilmetanamina
CL2022002986A1 (es) Compuestos derivados de azetidina-3-ilmetanol como moduladores del receptor ccr6
HN2007000702A (es) Proceso para la preparacion de compuestos 4- amino-2- (2,6- dioxopiperidina- 3- yl9 isoindolina--1,3-diona